No Data
No Data
Betta Pharmaceuticals Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Betta Pharmaceuticals: Summary of Half-Year Report in 2024.
Betta Pharmaceuticals: Half-year report for the year 2024.
Betta Pharmaceuticals (300558.SZ): Net income in the first half of the year was 0.224 billion yuan, a year-on-year increase of 51.00%.
On August 5th, Gelunhui reported that Betta Pharmaceuticals (300558.SZ) released its 2024 interim report, reporting revenue of CNY 1.501 billion, a YoY increase of 14.22%; net income attributable to shareholders of listed companies was CNY 0.224 billion, a YoY increase of 51.00%; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was CNY 0.217 billion, a YoY increase of 144.98%; and net cash flow from operating activities was CNY 0.522 billion, a YoY increase of 44.77%. In the first half of 2024, the company's R&D investment reached CNY 381.8533 million.
Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares
Betta Pharmaceuticals: 2024 Interim Performance Forecast
No Data